Masimo Posts Preliminary Q4, FY25 Results

Masimo reported preliminary Q4 revenue of roughly $411 million, up about 12% year-over-year (11% on a constant-currency basis), and expects adjusted EPS above $1.54 after accounting for new tariffs. For fiscal 2025 the company is forecasting revenue near $1.52 billion, about a 9% increase versus prior year, reflecting strength in its hospital monitoring business; the shares were trading near $138.24 on the Nasdaq.

Analysis

Market structure: Masimo's Q4/QFY preview (Q4 ~$411M, FY25 ~$1.52B, adj EPS > $1.54) signals durable hospital-monitoring demand and incremental pricing power in high-acuity sites; OEMs selling pulse-ox and monitoring stacks, service providers for hospitals, and component suppliers (sensors, ASICs) are direct beneficiaries, while low-cost competitors and import-dependent suppliers absorb tariff-driven cost inflation. Expect modest share gains vs. commoditized finger sensors if Masimo sustains differentiated algorithms; 10–12% YoY product growth in Q4 implies tighter demand vs. supply for high-end monitors over 3–12 months.

Risk assessment: Tail risks include FDA/regulatory action on sensor accuracy, renewed patent litigation losses, or tariff escalation that could compress gross margins by 200–400 bps within 6–12 months; reimbursement cuts represent a slower, multi-year downside. Near-term (days–weeks) risk is guidance revision or tariff detail; short-to-medium term (3–12 months) hinge on gross-margin recovery and product cadence; long-term depends on adoption in OR/ICU and recurring disposables revenue mix.

Trade implications: Favor idiosyncratic long exposure to MASI sized 2–3% of equity portfolios with disciplined stops (see decisions). Use a 9–12 month call-spread to cap cost if volatility rises around reported FY results; consider pair trade long MASI vs. short IHI to isolate device-specific outperformance. Fixed income and FX impact is negligible near-term, but improved earnings reduce equity volatility and could modestly tighten credit spreads for high-quality healthcare corporates.

Contrarian angles: Consensus mildly positive may underweight tariff drag and litigation volatility — upside is underappreciated if Masimo converts disposables to annuity-like revenue (target 30–40% attach-rate improvement over 12–24 months). Conversely, the market may be underestimating margin hit if tariffs persist; historical parallels (device makers rallying on growth then correcting on reimbursement/tariff beats) argue for hedged exposure and catalyst-based sizing.

Key Decisions for Investors

• Establish a tactical 2–3% net-long position in MASI (buy at market up to $138; add on pullbacks to <$130). Target a 20–25% total return over 6–12 months; trim half at +15% and fully exit at +25–30%. Set hard stop at -12% from entry.
• Implement a 9–12 month call spread for asymmetric upside: buy MASI Jan 2027 140 call and sell Jan 2027 190 call (or nearest strikes), size to cost ≤0.5% of portfolio; max loss = premium, aim for 30–40% upside capture if monitors adoption accelerates.
• Pair trade: long MASI 2% vs short iShares U.S. Medical Devices ETF (IHI) 1.5% to express stock-specific outperformance; rebalance after earnings and tighten if MASI misses tariff margin disclosure within 30 days.
• If risk-off or tariff details worsen, hedge with 3–6 month protective puts (MASI 12% OTM) or reduce position to 1% while monitoring two catalysts: formal tariff cost disclosure at full FY release (within 30 days) and any FDA/regulatory notices in the next 60–90 days.